Otsuka Pharmaceutical’s Lupkynis (voclosporin) is the first oral treatment to be approved in Europe for the treatment of active lupus nephritis (LN) in adult patients. The drug has received approval from the European Commission (EC) in combination with mycophenolate mofetil (MMF) for the treatment of adult patients with active class III, IV or V (including […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
